Assessing Safety, Tolerability and Pharmacokinetics of Rimegepant by Single and Multiple Dose as Compared to the Predicted Clinically Efficaciuos Dose Range Healthy Volunteers: A phase I study
Latest Information Update: 17 May 2020
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine; Trigeminal neuralgia
- Focus Adverse reactions; Pharmacokinetics
- 01 May 2020 Results assessing safety, tolerability and pharmacokinetics of Rimegepant doses (SAD and MAD) in healthy subjects presented at the 72nd Annual Meeting of the American Academy of Neurology
- 22 Nov 2019 New trial record